LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study.

    Benjamin, Laura A / Paterson, Ross W / Moll, Rachel / Pericleous, Charis / Brown, Rachel / Mehta, Puja R / Athauda, Dilan / Ziff, Oliver J / Heaney, Judith / Checkley, Anna M / Houlihan, Catherine F / Chou, Michael / Heslegrave, Amanda J / Chandratheva, Arvind / Michael, Benedict D / Blennow, Kaj / Vivekanandam, Vinojini / Foulkes, Alexander / Mummery, Catherine J /
    Lunn, Michael P / Keddie, Stephen / Spyer, Moira J / Mckinnon, Tom / Hart, Melanie / Carletti, Francesco / Jäger, Hans Rolf / Manji, Hadi / Zandi, Michael S / Werring, David J / Nastouli, Eleni / Simister, Robert / Solomon, Tom / Zetterberg, Henrik / Schott, Jonathan M / Cohen, Hannah / Efthymiou, Maria

    EClinicalMedicine

    2021  Volume 39, Page(s) 101070

    Abstract: ... of antiphospholipid antibodies in COVID-19 neurology remains unclear.: Methods: This single-centre cross-sectional study ... hospitalised patients with COVID-19. Characterisation of antiphospholipid antibody persistence and potential ... of patients with neurological manifestations and COVID-19; however, the pathogenicity ...

    Abstract Background: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear.
    Methods: This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ
    Findings: There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non-neurological COVID-hospitalised controls (76.6%) in contrast to the COVID-non-hospitalised controls (48.2%). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups (
    Interpretation: Our findings show that aPS/PT IgG is associated with COVID-19-associated ADEM. In contrast, aCL IgA and IgG are seen much more frequently in non-neurological hospitalised patients with COVID-19. Characterisation of antiphospholipid antibody persistence and potential longitudinal clinical impact are required to guide appropriate management.
    Funding: This work is supported by UCL Queen Square Biomedical Research Centre (BRC) and Moorfields BRC grants (#560441 and #557595). LB is supported by a Wellcome Trust Fellowship (222102/Z/20/Z). RWP is supported by an Alzheimer's Association Clinician Scientist Fellowship (AACSF-20-685780) and the UK Dementia Research Institute. KB is supported by the Swedish Research Council (#2017-00915) and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and theUK Dementia Research Institute at UCL. BDM is supported by grants from the MRC/UKRI (MR/V007181/1), MRC (MR/T028750/1) and Wellcome (ISSF201902/3). MSZ, MH and RS are supported by the UCL/UCLH NIHR Biomedical Research Centre and MSZ is supported by Queen Square National Brain Appeal.
    Language English
    Publishing date 2021-08-12
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2021.101070
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Antiphospholipid antibodies and neurological manifestations in acute COVID-19

    Laura A. Benjamin / Ross W. Paterson / Rachel Moll / Charis Pericleous / Rachel Brown / Puja R. Mehta / Dilan Athauda / Oliver J. Ziff / Judith Heaney / Anna M. Checkley / Catherine F. Houlihan / Michael Chou / Amanda J. Heslegrave / Arvind Chandratheva / Benedict D. Michael / Kaj Blennow / Vinojini Vivekanandam / Alexander Foulkes / Catherine J. Mummery /
    Michael P. Lunn / Stephen Keddie / Moira J. Spyer / Tom Mckinnon / Melanie Hart / Francesco Carletti / Hans Rolf Jäger / Hadi Manji / Michael S. Zandi / David J. Werring / Eleni Nastouli / Robert Simister / Tom Solomon / Henrik Zetterberg / Jonathan M. Schott / Hannah Cohen / Maria Efthymiou

    EClinicalMedicine, Vol 39, Iss , Pp 101070- (2021)

    A single-centre cross-sectional study

    2021  

    Abstract: ... of antiphospholipid antibodies in COVID-19 neurology remains unclear. Methods: This single-centre cross-sectional study included ... There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non ... of patients with neurological manifestations and COVID-19; however, the pathogenicity ...

    Abstract Background: A high prevalence of antiphospholipid antibodies has been reported in case series of patients with neurological manifestations and COVID-19; however, the pathogenicity of antiphospholipid antibodies in COVID-19 neurology remains unclear. Methods: This single-centre cross-sectional study included 106 adult patients: 30 hospitalised COVID-neurological cases, 47 non-neurological COVID-hospitalised controls, and 29 COVID-non-hospitalised controls, recruited between March and July 2020. We evaluated nine antiphospholipid antibodies: anticardiolipin antibodies [aCL] IgA, IgM, IgG; anti-beta-2 glycoprotein-1 [aβ2GPI] IgA, IgM, IgG; anti-phosphatidylserine/prothrombin [aPS/PT] IgM, IgG; and anti-domain I β2GPI (aD1β2GPI) IgG. Findings: There was a high prevalence of antiphospholipid antibodies in the COVID-neurological (73.3%) and non-neurological COVID-hospitalised controls (76.6%) in contrast to the COVID-non-hospitalised controls (48.2%). aPS/PT IgG titres were significantly higher in the COVID-neurological group compared to both control groups (p < 0.001). Moderate-high titre of aPS/PT IgG was found in 2 out of 3 (67%) patients with acute disseminated encephalomyelitis [ADEM]. aPS/PT IgG titres negatively correlated with oxygen requirement (FiO2 R=-0.15 p = 0.040) and was associated with venous thromboembolism (p = 0.043). In contrast, aCL IgA (p < 0.001) and IgG (p < 0.001) was associated with non-neurological COVID-hospitalised controls compared to the other groups and correlated positively with d-dimer and creatinine but negatively with FiO2. Interpretation: Our findings show that aPS/PT IgG is associated with COVID-19-associated ADEM. In contrast, aCL IgA and IgG are seen much more frequently in non-neurological hospitalised patients with COVID-19. Characterisation of antiphospholipid antibody persistence and potential longitudinal clinical impact are required to guide appropriate management. Funding: This work is supported by UCL Queen Square Biomedical Research Centre (BRC) and Moorfields ...
    Keywords Medicine (General) ; R5-920
    Subject code 616
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top